Anti-NCAM [ERIC-1]

Exclusive tool

NCAM, also known as CD56, is a homophillic binding glycoprotein present on a variety of neural cells including neurons, glia, skeletal muscle and natural killer cells.

Contributors

Inventor Institute
John Kemshead Institute of Child Health
SKU: 151092
Product description: NCAM, also known as CD56, is a homophillic binding glycoprotein present on a variety of neural cells including neurons, glia, skeletal muscle and natural killer cells. NCAM has been implicated as having a role in cell-cell adhesion, neurite outgrowth, synatptic plasticity, learning and memory and in the development of the nervous system.
Alternate name: Neural Cell Adhesion Molecule; NCAM; CD56 Antigen; MSK39
Conjugation: Unconjugated
Isotype: IgG1
Molecular weight: 180 kDa, 140 kDa, 120 kDa
Immunogen: Retinoblastoma tissue membrane fraction
Myeloma used: P3X63Ag8.653
Cat. #: 151092
Provenance and Ownership: The Anti-NCAM [ERIC-1] is owned by Cancer Research UK. CancerTools supplies the Anti-NCAM [ERIC-1] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-NCAM [ERIC-1] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements.
Tool sub type: Primary antibody
Unit size: 100 ug
Cancer types: Brain cancer
Research Fields: Cell biology; Cell signaling and signal transduction; Neurobiology; Stem cell biology
Application: ELISA ; FACS ; IHC ; IF ; IP ; RIA ; WB
Target: Neural Cell Adhesion Molecule (NCAM; CD56)
Reactivity: Human
Clone: ERIC-1
Host: Mouse
Class: Monoclonal
Primary citation: Bourne et al. 1991. J Neurooncol. 10(2):111-9. PMID: 1895159.
Target background: NCAM, also known as CD56, is a homophillic binding glycoprotein present on a variety of neural cells including neurons, glia, skeletal muscle and natural killer cells. NCAM has been implicated as having a role in cell-cell adhesion, neurite outgrowth, synatptic plasticity, learning and memory and in the development of the nervous system.
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Markovic-Lipkovski et al. 2015. PLoS One. 10(9):e0137028. PMID: 26327314.

Variable Expression of Neural Cell Adhesion Molecule Isoforms in Renal Tissue: Possible Role in Incipient Renal Fibrosis.

Klehr et al. 2009. J Immunother. 32(5):442-51. PMID: 19609236.

The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).

Pruszak et al. 2007. Stem Cells. 25(9):2257-68. PMID: 17588935.

Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations.

Blaheta et al. 2004. Neoplasia. 6(4):323-31. PMID: 15256054.

Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness.

Jensen et al. 2003. Clin Exp Immunol. 134(2):253-63. PMID: 14616785.

The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis.

Gerardy-Schahn et al. 1994. Int J Cancer Suppl. 8:38-42. PMID: 7515028.

Hot spots of antigenicity in the neural cell adhesion molecule NCAM.

Phimister et al. 1991. J Clin Pathol. 44(7):580-5. PMID: 1856291.

Expression of neural cell adhesion molecule (NCAM) isoforms in neuroblastoma.

Frost et al. 1991. Neuropathol Appl Neurobiol. 17(3):207-17. PMID: 1891065.

Expression of alternative isoforms of the neural cell adhesion molecule (NCAM) on normal brain and a variety of brain tumours.

Bourne et al. 1991. J Neurooncol. 10(2):111-9. PMID: 1895159.

A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumours arising from the neuroectoderm.

Images

View Gallery
Adapted from Markovi?-Lipkovski et al. 2015. PLoS One. 10(9)

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.